ONO Pharmaceutical Co(OPHLF)
$15.60+0.03 (+0.16%)
OPHLF
ONO Pharmaceutical Co stock drug pipeline
$15.60
At close:+0.03 (+0.16%)
ONO Pharmaceutical Co (OPHLF) Drug Pipeline
21 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does ONO Pharmaceutical Co (OPHLF) have in its pipeline
ONO Pharmaceutical Co OPHLF is currently developing the following drugs: Ono-4915, Ono-7429, Ono-6414, Ono-4538Hsc, Dcc-2618, Cenobamate For 12 To < 18 Year Olds, Cenobamate For 2 To < 18 Year Olds, Sapablursen, Tirabrutinib, Rituximab, Temozolomide, Tirabrutinib, Bevacizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Ono-4578, Opdivo, Ono-4538, Ono-2020, Ono-7428, Ono-1110, Ono-4059, Ono-7018, Cenobamate, Rituximab, Vincristine, Methotrexate, Ono-4059, Procarbazine, Ono-4685, Bevacizumab, Fluorouracil, Oxaliplatin, Cetuximab, Levofolinate, Ono-7913, Ono-4538, Nivolumab, Magrolimab, Bevacizumab, Fluorouracil, Oxaliplatin, Capecitabine, Ono-4538, Ono-4578, Calcium Levofolinate Hydrateb, Nivolumab, 5-Fu, Avastin, Abemaciclib, Palbociclib, Letrozole, Ono-4578, Fluorouracil, Oxaliplatin, Irinotecan, Levofolinate, Ono-7913, Ono-4538, Gemcitabine, Nab-Paclitaxel, Fluorouracil, Oxaliplatin, Irinotecan, Levofolinate, Ono-4538, Ono-4578, Gemcitabine, Nab-Paclitaxel, Ono-4538, Ono-7475, Ono-2910, Ono-7475, Osimertinib Mesylate, Ono-4538, Ono-7914, Oxaliplatin, Capecitabine, Nivolumab, S-1, Ono-4578, Opdivo, Ono-2808, Nivolumab, Oxaliplatin, Capecitabine, Ipilimumab, S-1, Ono-4538, Yervoy, Opdivo. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

